The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy
Abstract
Objective : To determine the efficacy of antiplatelet therapy in maintaining vascular patency in various categories of patients. Design : Overviews of 46 randomised trials of antiplatelet therapy versus control and 14 randomised trials comparing one antiplatelet regimen with another. Setting : Randomised trials that could have been available by March 1990 and in which vascular graft or arterial patency was to be studied systematically. Subjects : About 8000 patients at varying degrees of risk of vascular occlusion (by virtue of disease or of having some vascular procedure) were in trials of antiplatelet therapy versus control and 4000 such patients were in trials directly comparing different antiplatelet regimens. Results : Overall, antiplatelet therapy produced a highly significant (2P<0.00001) reduction in vascular occlusion, with similar proportional reductions in several different types of patient. Hence the absolute reductions tended to be largest among patients at highest risk of occlusion, with smaller but still significant absolute reductions among lower risk patients. The proportions of patients with confirmed occlusion among those allocated antiplatelet therapy versus appropriately adjusted control proportions (and mean scheduled treatment durations and net absolute benefits) were: (a) among about 4000 patients with coronary artery grafts, 21% antiplatelet therapy v 30% control (seven month benefit about 90 patients protected per 1000 allocated antiplatelet therapy (2P<0.00001); (b) among about 800 patients after coronary angioplasty, 4% antiplatelet therapy upsilion 8% control (six month benefit about 40/1000 (2P = 0.02)); (c) among about 3000 patients with peripheral artery procedures or disease, 16% antiplatelet therapy v 25% control (19 month benefit about 90/1000 (2P<0.00001); (d) among about 400 renal patients with a shunt or fistula placed for haemodialysis access, 17% antiplatelet therapy v 39% control (two month benefit about 200/1000 (2P<0.00001)). Conclusion : Antiplatelet therapy (chiefly aspirin alone or aspirin plus dipyridamole) greatly reduces the risk of vascular occlusion in a wide range of patients at high risk of this complication. Further studies are required to determine exactly when treatment should start (to limit any perioperative bleeding while still preventing most early occlusion) and for how long it should be continued.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Isolated noncompaction of left ventricular myocardium. A study of eight cases.
Chin, T. K., Perloff, J. K., Williams, R. G., Jue, K., & Mohrmann, R. (1990) · Circulation · doi:10.1161/01.cir.82.2.507 · Cited by 1,418
The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.
Farrell, B., Godwin, J., Richards, S., & Warlow, C. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.12.1044 · Cited by 1,203
Secondary prevention of vascular disease by prolonged antiplatelet treatment
Antiplatelet Trialists' Collaboration (1988) · BMJ · doi:10.1136/bmj.296.6618.320 · Cited by 1,047
Serruys, P. W., Luijten, H. E., Beatt, K. J., Geuskens, R., de Feyter, P. J., van den Brand, M., Reiber, J. H., ten Katen, H. J., van Es, G. A., & Hugenholtz, P. G. (1988) · Circulation · doi:10.1161/01.cir.77.2.361 · Cited by 931
Percutaneous Transluminal Coronary Angioplasty in 1985–1986 and 1977–1981
Detre, K., Holubkov, R., Kelsey, S., Cowley, M., Kent, K., Williams, D., Myler, R., Faxon, D., Holmes, D., Bourassa, M., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802043180501 · Cited by 851
Efron, B., & Morris, C. (1977) · Scientific American · doi:10.1038/scientificamerican0577-119 · Cited by 739
Schwartz, L., Bourassa, M. G., Lespérance, J., Aldridge, H. E., Kazim, F., Salvatori, V. A., Henderson, M., Bonan, R., & David, P. R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182603 · Cited by 692
CAMPEAU, L. A., Enjalbert, M., Lespérance, J., Bourassa, M. G., Kwiterovich, P. O., Wacholder, S., & Sniderman, A. D. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411223112101 · Cited by 621
Chesebro, J. H., Clements, I. P., Fuster, V., Elveback, L. R., Smith, H. C., Bardsley, W. T., Frye, R. L., Holmes, D. R., Vlietstra, R. E., Pluth, J. R., et al. (1982) · New England Journal of Medicine · doi:10.1056/nejm198207083070201 · Cited by 537
Effect of Dipyridamole and Aspirin on Late Vein-Graft Patency after Coronary Bypass Operations
Chesebro, J. H., Fuster, V., Elveback, L. R., Clements, I. P., Smith, H. C., Holmes, D. R., Bardsley, W. T., Pluth, J. R., Wallace, R. B., Puga, F. J., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198401263100401 · Cited by 516
Goldman, S., Copeland, J., Moritz, T., Henderson, W., Zadina, K., Ovitt, T., Doherty, J., Read, R., Chesler, E., & Sako, Y. (1988) · Circulation · doi:10.1161/01.cir.77.6.1324 · Cited by 424
Peto, R. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060306 · Cited by 409
United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results
Uk-Tia Study Group (1988) · BMJ · doi:10.1136/bmj.296.6618.316 · Cited by 388
IMPROVED AORTOCORONARY BYPASS PATENCY BY LOW-DOSE ASPIRIN (100 mg DAILY)
Lorenz, R. L., Weber, M., Kotzur, J., Theisen, K., Schacky, C. V., Meister, W., Reichardt, B., & Weber, P. C. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92446-2 · Cited by 320
Prevention of Thrombosis in Patients on Hemodialysis by Low-Dose Aspirin
Harter, H. R., Burch, J. W., Majerus, P. W., Stanford, N., Delmez, J. A., Anderson, C. B., & Weerts, C. A. (1979) · New England Journal of Medicine · doi:10.1056/nejm197909133011103 · Cited by 251
Goldman, S., Copeland, J., Moritz, T., Henderson, W., Zadina, K., Ovitt, T., Kern, K. B., Sethi, G., Sharma, G. V., & Khuri, S. (1991) · Circulation · doi:10.1161/01.cir.84.2.520 · Cited by 178
Collins, R., Gray, R., Godwin, J., & Peto, R. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060308 · Cited by 178
Pantely, G. A., Goodnight, S. H., Rahimtoola, S. H., Harlan, B. J., DeMots, H., Calvin, L., & Rösch, J. (1979) · New England Journal of Medicine · doi:10.1056/nejm197911013011803 · Cited by 171
Brown, B. G., Cukingnan, R. A., DeRouen, T., Goede, L. V., Wong, M., Fee, H. J., Roth, J. A., & Carey, J. S. (1985) · Circulation · doi:10.1161/01.cir.72.1.138 · Cited by 167
Prevention of aorta-coronary bypass graft occlusion
Limet, R., David, J.-L., Magotteaux, P., Larock, M.-P., & Rigo, P. (1987) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)36194-x · Cited by 166
Arteriovenous-Shunt Thrombosis
Kaegi, A., Pineo, G. F., Shimizu, A., Trivedi, H. L., Hirsh, J., & Gent, M. (1974) · New England Journal of Medicine · doi:10.1056/nejm197402072900604 · Cited by 144
McEnany, M. T., Salzman, E. W., Mundth, E. D., et al. (1982) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)37328-3 · Cited by 130
Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease.
Fuster, V., & Chesebro, J. H. (1986) · Circulation · doi:10.1161/01.cir.73.2.227 · Cited by 130
Pfisterer, M., Jockers, G., Regenass, S., Schmitt, H. E., Skarvan, K., Hasse, J., Burkart, F. E., Meyer, B., Burckhardt, D., Müller‐Brand, J., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90253-5 · Cited by 123
van der Meer, J., Hillege, H. L., van Gilst, W. H., Lie, K. I., Kootstra, G. J., Ascoop, C., & Pfisterer, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)91815-4 · Cited by 109
Sánz, G., Pajarón, A., Alegría, E., Coello, I., Cardona, M., Fournier, J. A., Gómez-Recio, M., Ruano, J., Hidalgo, R., & Medina, A. (1990) · Circulation · doi:10.1161/01.cir.82.3.765 · Cited by 94
Coronary artery bypass surgery and coronary angiography in the United States, 1979–1983
Gillum, R. F. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90952-5 · Cited by 78
Andrássy, K., Malluche, H. H., Bornefeld, H., Comberg, M., Ritz, E., Jesdinsky, H. J., & M�hring, K. (1974) · Journal of Molecular Medicine · doi:10.1007/bf01468835 · Cited by 71
Effects of sulfinpyrazone on early graft closure after myocardial revascularization
Baur, H. R., VanTassel, R. A., Pierach, C. A., et al. (1982) · The American Journal of Cardiology · doi:10.1016/0002-9149(82)90519-7 · Cited by 67
Brooks, N. H., Wright, J., Sturridge, M. F., Pepper, J., Magee, P., Walesby, R. K., Layton, C., Honey, M., & Balcon, R. (1985) · Heart · doi:10.1136/hrt.53.2.201 · Cited by 63
Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts
Rajah, S. M., Salter, M. C. P., Donaldson, D. M., Rao, R. S., Boyle, R. M., Partridge, J. B., & Watson, D. A. (1985) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(19)38592-7 · Cited by 62
Reocclusion Prophylaxis with Dipyridamole Combined with Acetylsalicylic Acid Following PTA
Heiss, H., Just, H., Middleton, D., & Deichsel, G. (1990) · Angiology · doi:10.1177/000331979004100402 · Cited by 60
Thromboprophylactic Effect of Ticlopidine in Arteriovenous Fistulas for Haemodialysis
Gröntoft, K., Mulec, H., Gutierrez, A., & Olander, R. (1985) · Scandinavian Journal of Urology and Nephrology · doi:10.3109/00365598509180223 · Cited by 60
FISKERSTRAND, C. E., Thompson, I. W., Burnet, M. E., Williams, P., & Anderton, J. L. (1985) · Artificial Organs · doi:10.1111/j.1525-1594.1985.tb04349.x · Cited by 57
Prevention of lipid accumulation in experimental vein bypass grafts by antiplatelet therapy.
Bonchek, L. I., Boerboom, L. E., Olinger, G. N., Pepper, J., Munns, J. R., Hutchinson, L. D., & Kissebah, A. H. (1982) · Circulation · doi:10.1161/01.cir.66.2.338 · Cited by 48
The Influence of Platelet Inhibition on the Patency of Femoro-Popliteal Dacron Bypass Grafts
Donaldson, D. M., Salter, M. C. P., Kester, R. C., Rajah, S. M., Hall, T., Sreeharan, N., & Crow, M. J. (1985) · Vascular Surgery · doi:10.1177/153857448501900405 · Cited by 44
GOLDMAN, M. D., & McCollum, C. N. (1984) · Vascular Surgery · doi:10.1177/153857448401800404 · Cited by 32
Meister, W., von Schacky, C., Weber, M. A., Lorenz, R. L., Kotzur, J., Reichart, B., Theisen, K., & Weber, P. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02407.x · Cited by 23
Antithrombotic therapy in the coronary vein graft patient
Israel, D. H., Fuster, V., Stein, B., Adams, P. C., Stein, B., & Chesebro, J. H. (1991) · Clinical Cardiology · doi:10.1002/clc.4960140403 · Cited by 22
Effect of Dipyridamole (Persantin®) on Blood Flow and Patency of Aortocoronary Vein Bypass Grafts
Ekeström, S., Gunnes, S., & Brodin, U. (1990) · Scandinavian Journal of Thoracic and Cardiovascular Surgery · doi:10.3109/14017439009098068 · Cited by 14
Thaulow, E., Fröysaker, T., Dale, J., & Vatne, K. (1987) · Scandinavian Journal of Thoracic and Cardiovascular Surgery · doi:10.3109/14017438709106027 · Cited by 12
Cited by
ACC/AHA guidelines for the management of patients with acute myocardial infarction
Committee Members, Ryan, T. J., Anderson, J. L., Antman, E. M., Braniff, B. A., Brooks, N. H., Califf, R. M., Hillis, L. D., Hiratzka, L. F., Rapaport, E., et al. (1996) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00392-0 · Cited by 1,850
Egger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Medical treatment of peripheral arterial disease and claudication
Hiatt, W. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442108 · Cited by 1,121
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02110-3 · Cited by 1,076
Aspirin as an Antiplatelet Drug
Wood, A. J. J., & Patrono, C. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301808 · Cited by 955
Metadata
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1994-01-15
- Volume
- 308
- Issue
- 6922
- Pages
- 159-168
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W4231595983
- Cited by
- 510
- References
- 42
- FWCI
- 20.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.